Subcutaneous XmAb7195: Phase Ib started

Xencor began a U.S. Phase Ib trial of once-weekly subcutaneous XmAb7195 in about 62 healthy volunteers and patients with atopic disease. An open-label part will compare 4 dose levels of subcutaneous X...